Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
説明 | Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I). |
ターゲット&IC50 | Abl (M351T):0.29 nM, Abl (H396P):0.35 nM, Abl:0.34 nM, Abl (Q252H):0.15 nM, Abl (E255K):0.27 nM |
In vitro | Administering 20 mg/kg of GZD824 daily inhibits tumor growth in syngeneic transplantation mice bearing Ba/F3 cells expressing Bcr-AblWT and BCR-AblT315I. Daily doses of 5 and 10 mg/kg GZD824 show a dose-dependent inhibition of tumor growth in xenograft models of K562 and KU812 tumors, without causing mortality or weight loss. |
In vivo | GZD824 effectively inhibits the activation of Bcr-Abl and its downstream targets, Crk1 and STAT5, in leukemia cells in a concentration-dependent manner. Its efficacy in inhibiting the proliferation of Ba/F3 cells expressing the Bcr-Abl T315I mutation and another 14 Bcr-Abl mutations associated with resistance aligns closely with results from biochemical kinase inhibition and protein binding affinity experiments. |
キナーゼ試験 | FRET-Based Z′-Lyte Assay Detecting Peptide Substrate Phosphorylation: The kinases ABL1, ABL1(E255K), ABL1 (G250E), ABL1(T315I), and ABL1(Y253F) are P3049, PV3864, PV3865, PV3866, and PV3863 are full-length human recombinant protein expressed in insect cells and histidine-tagged. Inhibition activities of inhibitors against Abl1 and its mutants are performed in 384-well plates using the FRET-based Z′-Lyte assay system. Briefly, the kinase substrate is diluted into 5 μL of kinase reaction buffer; and the kinase is added. Compounds (10 nL) with indicated concentrations are then delivered to the reaction by using Echo liquid handler, and the mixture is incubated for 30 min at room temperature. Then 5 μL of 2X ATP solution is added to initiate the reaction, and the mixture is further incubated for 2 h at room temperature. The resulting reactions contains 10 μM (for wild-type Abl1, and mutants Y253F, Q252H, M351T, and H396P) or 5 μM (for mutants E255K, G250E, T315I) of ATP, 2 μM of Tyr2 Peptide substrate in 50 mM HEPES (PH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.0247 μg/mL Abl1, and inhibitors as appropriate. Then, 5 μL of development reagent is added, and the mixture is incubated for 2 h at room temperature before 5 μL of stop solution is added. Fluorescence signal ratio of 445 nm (Coumarin)/520 nm (fluorescin) is examined on an EnVision Multilabel Reader. The data are analyzed using Graphpad Prism5. The data are the mean value of three experiments. |
細胞研究 | Cells in the logarithmic phase are plated in 96-well culture dishes. Twenty-four hours later, cells are treated with the corresponding compounds or vehicle control at the indicated concentration for 72 h. CCK-8 is added into the 96-well plates (10 μL/well) and incubated with the cells for 3 h. OD450 and OD650 are determined by a microplate reader. Absorbance rate (A) for each well is calculated as OD450 – OD650. The cell viability rate for each well is calculated as V% = (As – Ac)/(Ab – Ac) × 100%, and the data were further analyzed using Graphpad Prism5. The data are the mean value of the three experiments. As is the absorbance rate of the test compound well, Ac is the absorbance rate of the well without either cell or test compound, and Ab is the absorbance rate of the well with cell and vehicle control.(Only for Reference) |
別名 | GZD824 Dimesylate, HQP1351 |
分子量 | 724.77 |
分子式 | C29H27F3N6O·2CH4O3S |
CAS No. | 1421783-64-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: 92 mg/mL (126.9 mM)
DMSO: 93 mg/mL (128.3 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Olverembatinib dimesylate 1421783-64-3 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl region-Abelson phosphorylated imatinib GZD824 Dimesylate inhibit linase Inhibitor HQP-1351 nonphosphorylated breakpoint resistance GZD-824 Dimesylate HQP 1351 HQP1351 dimesylate Olverembatinib Dimesylate GZD 824 Dimesylate GZD-824 GZD824 Bcr-Abl(T315I) GZD 824 HQP1351 cluster Olverembatinib inhibitor